ArticlePloS one2026
Differential analysis of Short chain fatty acids incubation in autistic organoids based on transcriptome sequencing.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autism spectrum disorder (ASD) is characterized by difficulty with social communication and restricted, repetitive patterns of behavior, interest, or activities. We hypothesized that a dysregulation in short-chain fatty acid (SCFA) metabolism induces metabolic dysregulation and proinflammatory responses, which collectively contribute to the social behavioral deficits observed in early childhood. Herein, by high-throughput RNA sequencing (RNA-seq) of the whole transcriptome, including GO and KEGG enrichment analyses, we analyzed global gene expression differences in ASD cerebral organoids exposed to different SCFAs. The ASD cerebral organoids were divided into three groups: the ASD group (control), the acetate-treated group (Z group), and the butyrate-treated group (J group), with three biological replicates per group. Organoids were treated with 100 μM sodium acetate or 100 μM sodium butyrate from day 16 to day 23 of cortical differentiation, for a total duration of 7 days. GO functional annotation revealed that acetate treatment primarily altered gene expression related to differential regulation, whereas butyrate exposure activated immune-related processes. KEGG pathway analysis indicated that butyrate treatment was associated with enrichment of the TGF-β immune-related signaling pathway in ASD organoids, whereas acetate treatment primarily affected molecular functions such as transcriptional regulation, catalytic activity, and membrane permeability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.